WST · West Pharmaceutical Services Inc

Track WST — free

$370.76 -5.87 (-1.56%) At close · Sep 30

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$26.07B

70.38M

Volume · Sep 30 471.18K Avg daily vol (3M) 644.35K

Up next

Next earnings call

Oct 22, 2026 Est · unconfirmed · in 3 wks

Latest filing: 10-Q

filed Jul 23, 2026

Q2 2026 earnings call transcript

call held Jul 23, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$3.33B

Trailing 12 months

Net income (TTM)

$564.90M

Trailing 12 months

Revenue growth YoY

+13.8%

Year over year

Operating margin

20.5%

Trailing 12 months

P / E (TTM)

48.2

Trailing earnings · reciprocal yield 2.1%

FCF yield

1.7%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

-1.7%

Year over year · fewer shares

Price change (1Y)

+44.7%

Trailing year

Short interest

3.4%

Latest settlement · 4.5 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Moderate

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +23%

above

Price vs 50-day avg +5%

above

RSI (14) 60

neutral

MACD trend Positive

52-week position 96%

near high

Momentum

relative strength

Very Strong

1-month return +9%

trailing

6-month return +43%

trailing

YTD return +35%

this year

Relative strength +31%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $352 › 200d $301 — 50d above 200d

Institutional flow Accumulating

+10% holders QoQ · +149 funds added

Insider flow Distributing

Net -$2.8M over 90 days · 100% sells

Short interest Rising

3.38% of float · ▲ +8.3% MoM · 4.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

835 holders — near 3-yr high, broad support

Squeeze score 56

elevated · 0–100

Fundamentals

Strong

Revenue growth +2%

Y/Y

Gross margin 38%

expanding

EPS growth +1%

Y/Y

Free cash flow $468.9M

Valuation P/E 47.4

in line

Balance sheet $588.5M

net cash

Quant / Vol

risk profile

Moderate

Volatility 33%

annualized · 1-yr

Max drawdown −25%

past year

ATR 2.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 5 of last 8

Latest guidance · from the 8-K filed Jul 23, 2026

Full-Year 2026

Full-year 2026 net sales Initiated $3.35B – $3.38B

prior FY $3.07B midpoint +9.4% Y/Y

Full-year 2026 adjusted-diluted EPS Non-GAAP Initiated $8.85 – $9.05

Full-year 2026 capital spending Initiated $250M – $275M

Third-Quarter 2026

Third-quarter 2026 net sales $820M – $835M

prior qtr $872.3M midpoint −5.1% QoQ

Third-quarter 2026 adjusted-diluted EPS Non-GAAP $2.14 – $2.24

2026 Annual

Capital Expenditure Initiated $250M – $275M

Guided vs delivered · last 8 settled

Full-year 2023 net sales guidance full-year 2023

guided $2.95B – $2.96B

guided $2.95B – $2.96B $2.95B Miss −0.2%

Reported-diluted EPS 2023 Full-Year

guided $7.74 – $7.79

guided $7.74 – $7.79 $7.88 Beat +1.5%

Net sales full-year 2022

guided $3.05B – $3.08B

guided $3.05B – $3.08B $2.89B Miss −5.7%

Diluted EPS full-year 2022

guided $9.20 – $9.35

guided $9.20 – $9.35 $7.73 Miss −16.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 2 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+23% Bullish

Price vs 50-day avg

+5% Bullish

RSI (14)

60 Neutral

MACD trend

Positive Bullish

52-week position

96% Bullish

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $352 › 200d $301 — 50d above 200d

Institutional flow Accumulating

+10% holders QoQ · +149 funds added

Insider flow Distributing

Net -$2.8M over 90 days · 100% sells

Short interest Rising

3.38% of float · ▲ +8.3% MoM · 4.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

835 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $231 Now $371 · 96% Range high $377

vs 200-day avg +23% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted diluted EPS non-GAAP	$2.37	Three months ended June 30, 2026 filing	—
Adjusted net income non-GAAP	$169.4M	Three months ended June 30, 2026 filing	—
Adjusted operating profit non-GAAP	$197.4M	Three months ended June 30, 2026 filing	—
Consolidated net sales organic growth non-GAAP	12.7%	Three Months Ended June 30, 2026 filing	—
Proprietary Products net sales organic growth non-GAAP	15.5%	Three Months Ended June 30, 2026 filing	—
West Vantage net sales organic growth non-GAAP	0.8%	Three Months Ended June 30, 2026 filing	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
WST West Pharmaceutical Services Inc this stock	$26.07B	+34.8%	+2.0%	47.4	3.4%
ISRG Intuitive Surgical Inc	$143.14B	-28.2%	+20.5%	46.5	2.3%
BDX Becton Dickinson & Co	$49.57B	—	+8.2%	—	4.2%
MDLN Medline Inc.	$45.62B	-17.4%	+11.5%	—	3.1%
RMD Resmed Inc	$32.02B	-8.2%	+13.4%	21.3	9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

835

% held: 100.6%
Net QoQ: -1.0M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

777

View

Short & Settlement

Short Interest Rising

Shares short

2.4M

Days to cover: 4.5d
Change: +182.4K sh

View

Short Volume

Short vol %

42%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $6.1K
As of: Sep 8, 2026

View

Off-Exchange

Off-exchange %

44.6%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$2.8M

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Congressional Trades Sell

Member

Lisa McClain

Amount: $1.0K–$15.0K
Traded: Jul 22, 2025

View

Financials

Revenue (FY)

$3.1B

Net income (FY): $493.7M
EPS diluted: $6.79

View

Buybacks

Authorized

shares 1.0B

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 23, 2026
This year: 13

View

Proposed Sales

Value

$1.1M

Shares: 3.4K
Filed: May 7, 2026

View

Earnings & Events

Earnings Calls

Last call

Jul 23, 2026

View

Performance

	5D	20D	120D	MTD	YTD
WST	-1.4%	+9.5%	+43.4%	+8.7%	+34.8%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	-0.7%	+9.4%	+31.2%	+9.3%	+22.9%

Capital returns

Buyback program · as of Feb 28, 2026

Authorized

shares 1.00B

Spent (derived)

—

Remaining

—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 105770 CUSIP 955306105 13F (30d) 19 filings 15 filers Visit website Investor relations

WST · West Pharmaceutical Services Inc

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns